Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities.

Bone marrow transplantation·2026
Same author

The role of allogeneic stem cell transplantation in peripheral T-cell lymphoma.

Bone marrow transplantation·2026
Same author

T-cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Bone marrow transplantation·2026
Same author

Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow Transplantation.

Haematologica·2026
Same author

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Blood advances·2026
Same author

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

The Lancet. Haematology·2026

Related Experiment Video

Updated: May 26, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Impact of valproic acid on dendritic cells function.

Jihane Frikeche1, Thomas Simon, Eolia Brissot

  • 1INSERM CRNCA UMR892, Nantes, France.

Immunobiology
|January 3, 2012
PubMed
Summary

Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, alters dendritic cell (DC) function by downregulating key surface markers and inhibiting cytokine production. This impacts T cell responses, suggesting careful immune monitoring for patients on HDAC inhibitors.

More Related Videos

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

Related Experiment Videos

Last Updated: May 26, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Histone deacetylase (HDAC) inhibitors exhibit anti-inflammatory and immunomodulatory effects.
  • Valproic acid (VPA) is an HDAC inhibitor with potential therapeutic applications.

Purpose of the Study:

  • To investigate the impact of VPA on dendritic cell (DC) differentiation and function.
  • To assess VPA's influence on DC phenotype, cytokine production, and T cell activation.

Main Methods:

  • Monocytes were differentiated into DCs in the presence or absence of VPA.
  • Phenotypic analysis of mature DCs was performed using flow cytometry.
  • Cytokine production (IL-10, IL-12p70) by DCs was measured.
  • Allogeneic mixed lymphocyte reactions were used to assess T cell responses.

Main Results:

  • VPA did not impair DC differentiation but downregulated CD40, CD80, CD86, CD83, and HLA-DR on mature DCs.
  • VPA significantly inhibited IL-10 and IL-12p70 production by DCs.
  • DCs treated with VPA reduced the proportion of IFN-gamma+ CD4+ T cells and Granzyme B expression in CD8+ T cells.

Conclusions:

  • HDAC inhibition by VPA alters critical human DC functions.
  • Monitoring immune function is crucial for cancer patients receiving HDAC inhibitors.
  • VPA demonstrates potential as a therapeutic agent for inflammatory and autoimmune diseases.